All lobbying filings

THE MCMANUS GROUP

Lobbying for ROCHE DIAGNOSTICS · Diagnostic test manufacturing

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Income

$40,000.00

What the client paid this registrant for the period.

Client based in

Indiana

Official filing document

Government bodies contacted 4

Centers For Medicare and Medicaid Services (CMS)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 2

HR 5343
Ensuring Patient Access to Critical Breakthrough Products Act
S 1717
Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Lobbying activity 1

Medicare/Medicaid

Access to and reimbursement of medical devices, specifically diagnostics, in the Medicare program. Issues related to Medicare reimbursement for clinical laboratory services under the Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) of 2014. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.